Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... and improvement in some cholesterol parameters, with a very small increase in heart rate.

No difference in thyroid cancer risk was found for adults with type 2 diabetes using a GLP-1 receptor agonist vs ... number of thyroid cancer cases was small, medullary thyroid cancer risk ...

Novo Nordisk's amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a phase 1b/2a study in patients with obesity or overweight after 36 weeks ...

It has similar efficacy to other GLP1 agonists ... for CV events probably combine to make GLP-1 RAs protective against CV events. However, recent small studies on both animals and humans have ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Fortunately, large scale randomised trials with GLP-1RA-based therapies that yield greater weight loss are ongoing and several will report out in the next 1 ... agonists, as expected gastrointestinal ...

Jonathan Wolleben’s rating is based on the significant potential he sees in Structure Therapeutics, Inc., particularly due to its position as a leader in small molecule amylin agonists.